Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (RADAR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01356849
First received: April 19, 2011
Last updated: August 20, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2012
  Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 20, 2013